查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1406653

下一代糖尿病治疗和药物传输市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按产品类型、适应症、最终用户、地区和竞争细分

Next Generation Diabetes Therapy and Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Indication, By End user, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球下一代糖尿病治疗和药物输送市场价值为 222.5 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年复合CAGR为7.25%。糖尿病是一种影响全球数百万人的慢性疾病，其管理需要持续努力控制血糖水平并预防併发症。近年来，由于创新研究和技术，糖尿病治疗和药物传输领域取得了显着进展。全球下一代糖尿病治疗和药物输送市场正处于变革的风口浪尖，为糖尿病患者带来了新的希望。糖尿病是一种代谢性疾病，其特征是血糖水平升高，这是由于身体无法产生足够的胰岛素或有效利用其产生的胰岛素所造成的。如果处理不当，可能会导致严重的併发症，如心臟病、肾臟问题、视力丧失和神经病变。有效的糖尿病治疗和药物传递对于帮助患者过更健康的生活至关重要。

下一代糖尿病治疗和药物传递的全球市场正在快速扩张。导致这种增长的因素有很多，包括全球糖尿病发病率上升、技术进步以及人们对糖尿病管理重要性的认识不断提高。糖尿病治疗和药物传递创新的关键驱动力之一是技术的进步。连续血糖监测 (CGM) 系统、胰岛素帮浦和智慧胰岛素笔是彻底改变患者管理糖尿病方式的尖端技术的一些例子。这些设备提供即时资料并自动输送胰岛素，提高精度和便利性。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 222.5亿美元
2028 年市场规模 332.2亿美元
2023-2028 年CAGR 7.25%
成长最快的细分市场 亚太地区
最大的市场 北美洲

日益严重的糖尿病流行正在推动全球下一代糖尿病治疗和药物传输市场

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：全球下一代糖尿病治疗与药物传递市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（吸入胰岛素、口服胰岛素、胰岛素贴片、CGM 系统、人工胰臟）
    • 依适应症（1 型糖尿病、2 型糖尿病）
    • 按最终使用者（诊断/诊所、重症监护病房 (ICU)、家庭医疗保健）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按地区

第 5 章：亚太地区下一代糖尿病治疗与药物传递市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国下一代糖尿病治疗和药物输送
    • 印度下一代糖尿病治疗和药物输送
    • 澳洲下一代糖尿病治疗和药物输送
    • 日本下一代糖尿病治疗与药物输送
    • 韩国下一代糖尿病治疗和药物输送

第 6 章：欧洲下一代糖尿病治疗与药物输送市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美下一代糖尿病治疗与药物传递市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲下一代糖尿病治疗与药物传递市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲下一代糖尿病治疗和药物传输市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非下一代糖尿病治疗和药物输送
    • 沙乌地阿拉伯下一代糖尿病治疗和药物输送
    • 阿联酋下一代糖尿病治疗和药物输送
    • 埃及下一代糖尿病治疗与药物输送

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 12 章：全球下一代糖尿病治疗与药物输送市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 雅培实验室
    • Business Overview
    • Company Snapshot
    • Product & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 德克斯康沃尔
  • 礼来公司
  • Enteris BioPharma Inc.（Swk 控股公司）
  • 格莱森公司
  • 曼肯德公司
  • 美敦力公司
  • 赛诺菲公司
  • Senseonics 控股

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 20093

Global Next Generation Diabetes Therapy and Drug Delivery Market has valued at USD 22.25 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. Diabetes is a chronic disease that affects millions of people worldwide, and its management requires ongoing efforts to control blood sugar levels and prevent complications. The field of diabetes therapy and drug delivery has seen remarkable progress in recent years, thanks to innovative research and technology. The global next-generation diabetes therapy and drug delivery market is on the cusp of transformative change, offering new hope for individuals living with diabetes. Diabetes is a metabolic disorder characterized by elevated blood sugar levels, resulting from the body's inability to produce enough insulin or effectively utilize the insulin it produces. It can lead to serious complications such as heart disease, kidney problems, vision loss, and neuropathy if not properly managed. Effective diabetes therapy and drug delivery are essential to help patients lead healthier lives.

The global market for next-generation diabetes therapy and drug delivery is undergoing rapid expansion. Several factors contribute to this growth, including a rising global incidence of diabetes, technological advancements, and increased awareness about the importance of diabetes management. One of the key drivers of innovation in diabetes therapy and drug delivery is the advancement of technology. Continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin pens are some examples of cutting-edge technologies that have revolutionized the way patients manage their diabetes. These devices provide real-time data and automate insulin delivery, improving precision and convenience.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 22.25 Billion
Market Size 2028USD 33.22 Billion
CAGR 2023-20287.25%
Fastest Growing SegmentAsia Pacific
Largest MarketNorth America

Growing Diabetes Epidemic is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market

The global diabetes epidemic is a major public health concern, affecting individuals of all ages and backgrounds. According to the International Diabetes Federation (IDF), in 2019, there were approximately 463 million adults living with diabetes, and this number is projected to rise to 700 million by 2045 if current trends persist. The majority of diabetes cases are of the type 2 variety, which is closely linked to lifestyle factors such as poor diet and physical inactivity. The impact of diabetes goes beyond health concerns, as it places a significant economic burden on healthcare systems. Diabetes-related medical expenses and lost productivity have a substantial economic cost, both on a global and individual scale. Recognizing the dire need for more effective and patient-friendly treatments, the Next Generation Diabetes Therapy and Drug Delivery market has witnessed significant growth. Innovations in this field aim to address the unique challenges faced by people with diabetes, ultimately leading to better disease management and improved quality of life.

Traditional insulin injections are often inconvenient and painful for individuals with diabetes. The development of advanced insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, has revolutionized diabetes management. These devices offer precise insulin delivery, reduce the risk of hypoglycemia, and provide real-time glucose monitoring, thus improving overall glycemic control. Researchers have been working on developing an oral insulin delivery method, which would eliminate the need for injections. This technology has the potential to significantly improve patient adherence to treatment regimens. The concept of an artificial pancreas is a game-changer in diabetes therapy. It combines continuous glucose monitoring with automated insulin delivery, creating a closed-loop system that can respond to fluctuations in blood glucose levels in real-time. Such innovations offer the promise of better blood sugar control and fewer diabetes-related complications. Advances in genomics and personalized medicine have enabled the development of diabetes treatments tailored to an individual's genetic makeup. These treatments may prove to be more effective and have fewer side effects than traditional therapies. Telemedicine and digital health solutions have become integral in diabetes management. They provide remote monitoring and support, allowing healthcare professionals to track patients' progress and adjust treatment plans as necessary.

The global Next Generation Diabetes Therapy and Drug Delivery market is expected to grow significantly in the coming years. Factors such as the increasing prevalence of diabetes, the need for more patient-friendly treatment options, and ongoing research and development in the field of diabetes management contribute to this growth. The market is also likely to witness collaborations between pharmaceutical companies, medical device manufacturers, and digital health companies to offer comprehensive solutions for diabetes care. Furthermore, regulatory bodies around the world are increasingly supportive of innovation in diabetes management, streamlining the approval process for new therapies and devices. This has created a favorable environment for companies seeking to bring new products to the market.

Rising Healthcare Expenditure is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market

The rising healthcare expenditure worldwide, coupled with the growing prevalence of diabetes, has created a strong impetus for the development and adoption of next-generation diabetes therapy and drug delivery solutions. These innovative approaches offer the potential to reduce the economic and human toll of diabetes, improve patient outcomes, and enhance the sustainability of healthcare systems. As research and development in this field continue to progress, the future holds promise for individuals living with diabetes and those dedicated to providing them with the best care possible.

The growth of the global next generation diabetes therapy and drug delivery market is closely tied to the increasing healthcare expenditure seen in many countries. As the number of people living with diabetes continues to grow, healthcare systems are under increasing pressure to provide effective and cost-efficient solutions. Investing in next-generation therapies and drug delivery systems is seen as a way to address this challenge. Diabetes imposes a significant economic burden on both individuals and healthcare systems. The cost of treating diabetes-related complications, hospitalizations, and medications is substantial. Innovations in diabetes management can help reduce these costs and improve overall healthcare sustainability. The shift towards patient-centered care and the demand for improved quality of life has led to the development of next-generation therapies that focus on patient convenience, adherence, and outcomes. Advances in medical technology, data analytics, and artificial intelligence are driving the development of innovative solutions in diabetes management. These technologies not only improve patient care but also contribute to healthcare system efficiency.

Key Market Challenges

Regulatory and Approval Processes

One of the primary challenges in the global diabetes therapy market is the stringent regulatory environment. Developing new therapies and drug delivery methods requires extensive testing, clinical trials, and rigorous safety and efficacy assessments. Obtaining regulatory approval can be a long and costly process, often taking years. This can discourage smaller companies with innovative solutions from entering the market, as they may not have the resources to navigate the regulatory hurdles effectively.

Cost of Innovation

Innovation in diabetes therapy and drug delivery comes at a high cost. Developing and testing new technologies, medications, and delivery methods requires substantial investments in research and development. Many innovative therapies and drug delivery systems remain out of reach for patients due to their high price points. This cost can be a significant barrier to access for individuals with diabetes, particularly in low-income and underprivileged regions.

Patient Adherence

Patient adherence to diabetes therapies and drug delivery methods is a persistent challenge. Even with the introduction of innovative options, patients may struggle to follow their treatment regimens. This non-adherence can lead to suboptimal health outcomes and increased healthcare costs. There is a need for greater patient education, support, and user-friendly therapies to enhance adherence.

Integration of Digital Health Solutions

The integration of digital health solutions and technology into diabetes therapy and drug delivery is a promising avenue, but it comes with its own set of challenges. Ensuring data privacy and security while using apps, wearable devices, and telehealth platforms is critical. Additionally, not all patients have access to smartphones or the internet, potentially leaving some individuals with diabetes at a disadvantage.

Tailoring Therapies to Individual Needs

Diabetes is a highly individualized condition. What works for one patient may not work for another. Personalized medicine has the potential to revolutionize diabetes management, but developing tailored therapies and drug delivery methods can be complex and costly. It requires a deep understanding of a patient's genetic, metabolic, and lifestyle factors, which is not always feasible in routine clinical practice.

Global Disparities

Access to next-generation diabetes therapies and drug delivery methods is not evenly distributed around the world. High-income countries often have better access to cutting-edge treatments, while low and middle-income nations may face limited resources and infrastructure. Addressing these global disparities is a significant challenge in ensuring equitable diabetes care.

Competition and Market Saturation

As the global diabetes therapy and drug delivery market becomes more competitive, companies must continually innovate to stay ahead. However, the market may become saturated with similar products, making it difficult for newcomers to gain a foothold. Additionally, competitive pricing can lead to price wars that negatively impact profit margins.

Key Market Trends

Technological Advancements

Diabetes has emerged as a global health crisis, affecting millions of people worldwide. As the prevalence of diabetes continues to rise, so does the demand for innovative and effective treatments. Technological advancements are playing a pivotal role in shaping the next generation of diabetes therapy and drug delivery solutions, driving the growth of the global diabetes market. Continuous Glucose Monitoring (CGM) Systems have revolutionized diabetes management by providing real-time glucose level data. These devices, often paired with smartphone apps, enable patients and healthcare providers to monitor and adjust insulin levels more accurately. The development of smaller, more comfortable sensors and improved data accuracy has made CGM a game-changer in diabetes therapy. Artificial pancreas systems, also known as closed-loop systems, combine CGM technology with insulin pumps. These devices automatically adjust insulin delivery based on real-time glucose data, reducing the burden on patients and improving blood sugar control. The FDA's approval of such systems has further advanced the adoption of this technology. Traditional insulin pens and pumps have evolved into smart, connected devices that track insulin doses and provide reminders for patients. They allow healthcare providers to remotely monitor and adjust insulin regimens, enhancing patient care and compliance.

Smartphone apps and digital platforms provide patients with tools for tracking their glucose levels, medications, and dietary habits. These platforms also offer educational resources and connect patients with healthcare professionals, promoting self-management and facilitating more personalized treatment plans. Technological advancements have also led to the development of innovative drug delivery systems, such as inhalable insulin and smart patches. These solutions aim to improve the ease of insulin administration and reduce the stigma associated with diabetes treatment.

The convergence of these technological advancements has resulted in a booming market for next-generation diabetes therapy and drug delivery solutions. The global diabetes care devices market was valued at approximately $20 billion in 2020 and is expected to experience robust growth in the coming years. This growth is driven by the increasing prevalence of diabetes, rising patient awareness, and the demand for more convenient and efficient treatment options. Moreover, ongoing research and development in the field of diabetes technology are fueling innovation. Pharmaceutical and medical device companies are investing heavily in improving existing technologies and developing new solutions, which further propel the market's expansion.

Segmental Insights

Product Type Insights

Based on the category of Product Type, CGM Systems emerged as the dominant player in the global market for Next Generation Diabetes Therapy and Drug Delivery in 2022 Continuous Glucose Monitoring (CGM) systems are at the forefront of the next generation of diabetes therapy and drug delivery. These systems use tiny sensors inserted under the skin to measure glucose levels in the interstitial fluid continuously. The data collected is transmitted wirelessly to a receiver or smartphone, providing real-time glucose information, trends, and alerts. CGM systems offer immediate feedback on glucose levels, allowing individuals with diabetes to make informed decisions about their food intake, insulin dosages, and lifestyle choices. CGM systems help individuals maintain target glucose levels, reducing the risk of hypoglycemia and hyperglycemia, which can have severe consequences. These systems provide valuable insights into a person's unique glucose patterns, enabling healthcare professionals to create tailored treatment plans. CGM systems reduce the need for frequent fingerstick tests and simplify the diabetes management process, leading to a better quality of life for patients. CGM technology has continued to evolve, with each new generation of devices becoming more accurate, comfortable, and user-friendly. As these systems become more sophisticated, they offer more than just glucose data. Some CGM devices now provide predictive algorithms and even insulin dosing recommendations.

End user Insights

The Diagnostic/Clinics segment is projected to experience rapid growth during the forecast period. The diagnostic/clinics segment encompasses a wide range of services and tools designed to improve the diagnosis of diabetes and its complications. Early diagnosis is crucial in effective diabetes management, and the segment offers advanced screening tests, point-of-care diagnostics, and genetic testing, aiding in the timely identification of the condition. Clinics equipped with the latest diagnostic technologies can provide a more personalized approach to diabetes management. With the help of advanced diagnostics, healthcare professionals can tailor treatment plans to individual patients, resulting in better glycemic control and patient satisfaction.

Regional Insights

North America emerged as the dominant player in the global Next Generation Diabetes Therapy and Drug Delivery market in 2022, holding the largest market share in terms of value. North America boasts a well-established pharmaceutical and biotechnology sector, with numerous companies dedicated to diabetes research. Leading players, such as Eli Lilly, Novo Nordisk, and Johnson & Johnson, have their headquarters or major operations in the United States. This concentration of industry giants ensures a continuous stream of innovation and investment in diabetes care. North American institutions and universities conduct groundbreaking research in the field of diabetes, which often leads to the development of innovative therapies and drug delivery systems. Collaborations between academia and the private sector are commonplace, facilitating the translation of research findings into practical solutions. The regulatory framework in North America is stringent, ensuring that new therapies and drug delivery methods meet the highest safety and efficacy standards. This environment encourages the development of novel, effective solutions for diabetes management.

Key Market Players

Abbott Laboratories

Dexcom Inc.

Eli Lilly and Company

Enteris BioPharma Inc. (Swk Holdings Corporation)

GlySens Incorporated

MannKind Corporation

Medtronic plc

Sanofi S.A.

Senseonics, Holdings

Report Scope:

In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type:

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas

Next Generation Diabetes Therapy and Drug Delivery Market, By Indication:

  • Type 1 diabetes
  • Type 2 diabetes

Next Generation Diabetes Therapy and Drug Delivery Market, By End user:

  • Diagnostic/Clinics
  • Intensive Care Units (ICUs)
  • Home Healthcare

Next Generation Diabetes Therapy and Drug Delivery Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Next Generation Diabetes Therapy and Drug Delivery Market.

Available Customizations:

  • Global Next Generation Diabetes Therapy and Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
    • 4.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
    • 4.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Indication
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Indication
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Indication
        • 5.3.1.2.3. By End user
    • 5.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Indication
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Indication
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Indication
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Indication
        • 5.3.5.2.3. By End user

6. Europe Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Indication
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Indication
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Indication
        • 6.3.5.2.3. By End user

7. North America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Indication
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End user

8. South America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Indication
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End user

9. Middle East and Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Indication
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End user
    • 9.3.4. Egypt Next Generation Diabetes Therapy and Drug Delivery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Next Generation Diabetes Therapy and Drug Delivery Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Dexcom Inc.
  • 14.3. Eli Lilly and Company
  • 14.4. Enteris BioPharma Inc. (Swk Holdings Corporation)
  • 14.5. GlySens Incorporated
  • 14.6. MannKind Corporation
  • 14.7. Medtronic plc
  • 14.8. Sanofi S.A.
  • 14.9. Senseonics, Holdings

15. Strategic Recommendations

16. About Us & Disclaimer